Opendata, web and dolomites

BREAK SIGNED

Blue light remote analgesia with K+ channels

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BREAK project word cloud

Explore the words cloud of the BREAK project. It provides you a very rough idea of what is the project "BREAK" about.

first    network    solution    treatments    kept    thirds    invasiveness    neuropathic    break    characterised    investor    neuron    constitute    hospitals    fruitful    opioids    spectrum    synergy    patients    commercial    pain    medical    nausea    difficult    rats    prolonged    leveraging    hours    vivo    demonstrated    reporting    cells    genes    lower    version    optogenetic    restraining    class    diagnose    gt    implant    treatment    population    drugs    explore    nonspecific    stakeholder    chronic    pharma    minutes    normally    device    inhibitory    situation    treat    engineered    painful    nervous    genetically    origin    leads    interpret    tool       actually    optical    np    designed    lamp    weeks    stimuli    initiated    originally    virus    area    academic    illness    invasive    protein    drug    companies    progress    hard    antidepressants    20    12    abnormal    adoption    extremely    disorder    central    experiments    worse    causing    addiction    entities    damage    light    centers    skin    mostly    relief    plan    distance    proteins    silencing    despite    injected    exact    cp    peripheral    global    adults    partial    blink2    cm    brain    trauma    blue   

Project "BREAK" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI MILANO 

Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122
website: www.unimi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 150˙000.00

Map

 Project objective

Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks) originally initiated by a trauma or illness. Despite significant progress, CP remains extremely hard to treat, with only one-third to two-thirds of patients reporting adequate some pain relief. This situation is even worse for neuropathic pain (NP), a specific class of CP affecting 8% of global population and whose origin mostly depend on peripheral or central nervous damage or disorder, which leads the brain to interpret as pain normally non painful stimuli. NP is difficult to treat due to the large number of entities involved (cells, genes and proteins working in synergy), which makes it hard to rapidly diagnose the exact cause of pain. Drugs targeting the central nervous system (e.g. antidepressants and opioids) provide only partial pain relief and are nonspecific, also causing side effects like addiction, and nausea, thus restraining their adoption for prolonged treatments. BREAK is the first non-invasive inhibitory optogenetic tool specifically designed for NP treatment, with potential application to the whole spectrum of CP. BREAK is composed of a drug and an optical device. The protein BLINK2 is injected in the painful area using a genetically engineered virus, and respond to a specific blue light by silencing the addressed neuron. The lamp can be kept at some distance (cm) from the skin and no implant is required. Just some minutes of treatment results in hours of pain relief, making the invasiveness of BREAK far lower than actually existing solution. A first version of BREAK has already demonstrated in in-vivo experiments on rats. During this project we plan to further develop the treatment and explore its commercial potential. In particular, leveraging from the experience of different partners, we will constitute a fruitful stakeholder network, including Academic centers, hospitals, pharma companies and investor

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREAK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREAK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperBio (2019)

Vis-NIR Hyperspectral imaging for biomaterial quality control

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

ENTRAPMENT (2019)

Septins: from bacterial entrapment to cellular immunity

Read More